GO Description Count % Log10 ( Log10 (q ) Hits hsa05200 Pathways in cancer 17 51.52 −20.99 −18.57 CASP8, NQO1, EGFR, GSK3B, GSTP1, HMOX1, JUN, MYC, NFE2L2, MAPK1, PTEN, PTGS2, RB1, RELA, TGFB1, TGFB2, TP53 hsa05161 Hepatitis B 10 30.3 −14.91 −12.85 CASP8, JUN, MYC, MAPK1, RB1, RELA, TGFB1, TGFB2, TNF, TP53 hsa05163 Human cytomegalovirus infection 10 30.3 −13.47 −11.63 CASP8, EGFR, GSK3B, MYC, MAPK1, PTGS2, RB1, RELA, TNF, TP53 hsa04657 IL-17 signaling pathway 8 24.24 −13.07 −11.44 CASP8, GSK3B, JUN, MAPK1, PTGS2, RELA, TNF, TNFAIP3 hsa05418 Fluid shear stress and atherosclerosis 8 24.24 −11.69 −10.39 NQO1, GSTP1, HMOX1, JUN, NFE2L2, RELA, TNF, TP53 hsa05208 Chemical carcinogenesis - reactive oxygen species 8 24.24 −10.04 −8.9 NQO1, EGFR, HMOX1, JUN, NFE2L2, MAPK1, PTEN, RELA hsa04216 Ferroptosis 5 15.15 −9.08 −7.99 ALOX15, ACSL4, HMOX1, SLC3A2, TP53 hsa01524 Platinum drug resistance 4 12.12 −5.91 −5.22 CASP8, GSTP1, MAPK1, TP53 hsa05012 Parkinson disease 5 15.15 −5 −4.39 HSPA5, NFE2L2, SNCA, TP53, UCHL1 hsa04217 Necroptosis 4 12.12 −4.57 −3.98 ALOX15, CASP8, TNF, TNFAIP3 hsa04370 VEGF signaling pathway 3 9.09 −4.43 −3.86 HSPB1, MAPK1, PTGS2
